ArticleInternational journal of nanomedicine2026
Dendrocin ZM1 Nanoconjugates with Carbon Quantum Dots: A ROS-Generating Platform for Combating Multidrug-Resistant Bacteria.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The global increase in multidrug-resistant (MDR) bacterial infections highlights the urgent need for novel antimicrobial strategies. Antimicrobial peptides (AMPs), such as Dendrocin ZM1 derived from Methods: The nanoconjugates were synthesized and characterized using FTIR, XPS, TEM, DLS, and fluorescence spectroscopy. Antibacterial activity against MDR Gram-positive and Gram-negative strains was evaluated using MIC determination, time-killing kinetics, ROS production, and ROS-scavenger rescue experiments. Hemolysis and MTT assays assessed biocompatibility on human red blood cells and HEK-293 cells. Results: Dendrocin ZM1-CQDs showed a 2 to 4-fold reduction in MIC values compared with Dendrocin ZM1 alone, and its rapid bactericidal kinetics reached a reduction of ≥3-log Discussion: The synergistic combination of AMPs and CQDs offers a promising nanobiotechnology platform for next-generation antimicrobial therapeutics targeting MDR pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.